Buflomedil

Buflomedil

Names
IUPAC name 4-(pyrrolidin-1-yl)-1-(2,4,6-trimethoxyphenyl)butan-1-one
Identifiers
CAS Number	55837-25-7 Y
ChEMBL	ChEMBL188921 Y
ChemSpider	2373 Y
Jmol 3D model	Interactive image
PubChem	2467
UNII	V7I71DQ432 Y
InChI InChI=1S/C17H25NO4/c1-20-13-11-15(21-2)17(16(12-13)22-3)14(19)7-6-10-18-8-4-5-9-18/h11-12H,4-10H2,1-3H3 Y Key: OWYLAEYXIQKAOL-UHFFFAOYSA-N Y InChI=1/C17H25NO4/c1-20-13-11-15(21-2)17(16(12-13)22-3)14(19)7-6-10-18-8-4-5-9-18/h11-12H,4-10H2,1-3H3 Key: OWYLAEYXIQKAOL-UHFFFAOYAG
SMILES O=C(c1c(OC)cc(OC)cc1OC)CCCN2CCCC2
Properties
Chemical formula	C17H25NO4
Molar mass	307.38 g/mol
Pharmacology
ATC code	C04AX20
Vapor pressure	{{{value}}}
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Y verify (what is YN ?)
Infobox references

Buflomedil is a vasoactive drug used to treat claudication or the symptoms of peripheral arterial disease. It is currently not approved by the Food and Drug Administration (FDA) for use in the United States. Currently available as trade name tablet Loftyl

Toxicity

This drug might be suspended from marketing in the European Union, because of concerns about severe neurological and cardiac toxicity. In its press release dated 17 November 2011 EMA suggested that doctors "should stop using buflomedil and consider alternative treatment options".

Various adverse effects have been reported to the FDA.